« Back
Home /
Pomalidomide-PEG2-COOH

Pomalidomide-PEG2-COOH

Item no.	HY-131872-50mg
Manufacturer	MedChem Express
CASRN	2140807-17-4
Amount	50 mg
Quantity options	25 mg 50 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	99.87
Citations	[1]Fangqing Zhang, et al. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228.
Smiles	O=C(O)CCOCCOCCNC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	Pomalidomide 4'-PEG2-acid
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	E3 Ligase Ligand-Linker Conjugates
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	433.41
Product Description	Pomalidomide-PEG2-COOH (Pomalidomide 4'-PEG2-acid) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 62.5 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	PROTAC
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-131872-50mg-safety-datasheet.pdf